Who Is Buying Abbott Laboratories? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Abbott Laboratories (ABT) based on latest 13F filings. 8 funds buying including a new Renaissance position, Two Sigma and Balyasny exit.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Abbott Laboratories? Hedge Fund Activity in 2026
Abbott Laboratories is one of the most diversified healthcare companies in the world, operating across medical devices, diagnostics, nutrition, and established pharmaceuticals. The company behind FreeStyle Libre (the revolutionary continuous glucose monitor), a massive diagnostics portfolio, and household brands like Ensure and Similac has delivered consistent revenue growth through economic cycles. Abbott's combination of innovation and defensive characteristics makes it a cornerstone holding for many institutional portfolios.
The latest 13F filings reveal a decisively bullish picture: 8 funds are buying versus 6 selling, with 6 holding steady across 20 tracked funds. But the most dramatic events are two complete exits from major quant funds — and a notable new position from the world's most famous quantitative investor.
Quick Answer
Across the funds we read directly from SEC filings, the largest Abbott position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $780M (8,597,227 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Citadel Advisors, where Abbott is 0.5% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Abbott Laboratories Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 8 |
| Funds Selling | 6 |
| Funds Holding | 6 |
| Active Funds Tracked | 20 |
An 8-to-6 buy-sell ratio is a clear bullish tilt, particularly significant given the breadth of institutional coverage (20 funds). Abbott attracts attention from virtually every type of institutional investor — passive index funds, active fundamental managers, quant shops, and macro funds — making its 13F data an unusually comprehensive read on institutional sentiment.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho holds Abbott, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $780M | 8,597,227 | 0.5% of $171.84B |
| Millennium Management | $327M | 3,599,994 | 0.2% of $142.92B |
| Renaissance Technologies | $62M | 686,366 | 0.1% of $72.62B |
| Bridgewater Associates | $5.4M | 59,775 | 0.0% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Abbott that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Citadel Advisors | 1,915,846 | 8,597,227 | +349% |
| Millennium Management | 1,323,342 | 3,599,994 | +172% |
| Bridgewater Associates | 117,051 | 59,775 | -49% |
| Renaissance Technologies | 1,238,666 | 686,366 | -45% |
A fund absent from this table reported no Abbott position in either quarter.
Related Articles
- Who Is Buying Procter & Gamble? Hedge Fund Activity in 2026
- Who Is Buying McDonald's? Hedge Fund Activity in 2026
- Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
FAQ
What is a 13F filing and why does it matter for Abbott?
A 13F is a quarterly disclosure that institutional investment managers with over $100 million in US equity assets must file with the SEC, listing their long equity positions. Researchers and individual investors track 13F filings to see how large funds are positioning in widely held names like Abbott Laboratories — but the data is historical, lagged by up to 45 days, and excludes shorts and non-equity exposures.
Who are the largest institutional holders of Abbott Laboratories?
Index managers such as Vanguard, BlackRock and State Street hold the largest raw positions in almost every large-cap name, because they track the index rather than pick the stock. Among the active filers we read directly from EDGAR, the largest position in the Q2 2026 filings is Citadel Advisors at $780M (8,597,227 shares).
Why are Two Sigma and Balyasny exiting Abbott while Renaissance is initiating?
The simultaneous exits from Two Sigma and Balyasny alongside Renaissance Technologies' new ~$57.4M position reflect genuine disagreement between sophisticated quantitative and multi-manager models. This kind of divergence can indicate a statistical inflection point where small differences in model assumptions produce opposite conclusions, but the public 13F data alone does not reveal the underlying theses.
How does Abbott's healthcare exposure differ from a pure pharma name?
Abbott operates across four diversified segments — medical devices (notably FreeStyle Libre for continuous glucose monitoring), diagnostics, nutrition (Ensure, Similac), and established pharmaceuticals. This mix gives it more defensive characteristics than a single-product biotech, which is why investors often classify it as a quality compounder rather than a pure pharma play.
What does the overall institutional sentiment on Abbott look like in 2026?
Across 20 tracked funds, the latest snapshot shows 8 buying, 6 selling, and 6 holding — a net bullish tilt with notable cross-currents from the two complete exits. Investors use 13F data as one input among many; it reflects past positioning, not a forward recommendation, and should be combined with fundamentals, valuation, and personal risk tolerance.